Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance
FDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months